Company intelligence / Profile preview

ProImmune

Oxford, England, United Kingdomproimmune.com ↗

Ownership: Private
Employees: ~52
Development stage: Other

Overview

ProImmune does not develop its own therapeutic drugs but provides advanced platforms and services supporting preclinical and clinical immunology research. Its technologies are widely cited in peer-reviewed literature (>1800 publications) and used by leading pharma/biotech companies as well as academic/government labs.

Therapeutic areas: Immunology
Modalities: Protein (including recombinant proteins)Peptides (epitope mapping and antigen characterization)Assay services (ELISpot, flow cytometry)Antibody alternatives (Ankyrons®)Database/Platform technology (ProSentium™)
Industry: Drug Discovery Services

Partnerships

Not specifically listed; serves major pharmaceutical/biotech companies globally as customers.

Beyond the preview

Go deeper on ProImmune.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProImmune.

Explore the full profile